Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568–585

Article  CAS  PubMed  Google Scholar 

Rafael Canton Y, Doi, Patricia J, Simner (2022) Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Rev Anti-infective Therapy 20(8):1077–1094. https://doi.org/10.1080/14787210.2022.2071701

Article  CAS  PubMed  Google Scholar 

Çekin ZK, Dabos L, Malkoçoğlu G, Fortineau N, Bayraktar B, Iorga BI, Naas T, Aktaş E (2021) Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. Aeruginosa high-risk clones with VIM-5– and IMP-7–type carbapenemases in a tertiary hospital. Diagn Microbiol Infect Dis 99:115174

Article  PubMed  Google Scholar 

Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582–610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asempa TE, Nicolau DP, Kuti JL (2019) Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new b-lactam combination agents. J Clin Microbiol 57:e00535–e00519. https://doi.org/10.1128/JCM.00535-19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis JS, Weinstein MP, Bobenchik AM, Cameau S, Cullen SK, Dingle T et al Clinical and Laboratory Standards Institute. M100: performance standards for antimicrobial susceptibility testing

https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf

Young RJ et al (1997) Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 40(2):269–273

Article  CAS  PubMed  Google Scholar 

Tam VH et al (2003) Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 47(6):1853–1861

Article  CAS  PubMed  PubMed Central  Google Scholar 

Felton TW et al (2014) Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother 58(7):4094–4102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ong CT et al (2007) Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 57(2):153–161

Article  CAS  PubMed  Google Scholar 

Crandon JL et al (2010) Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 54(3):1111–1116

Article  CAS  PubMed  Google Scholar 

Leggett JE, Ebert ST, Fantin BR, Craig WA (1991) Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 74(Suppl 1):179–84

Leggett JE et al (1989) Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159(2):281–292

Article  CAS  PubMed  Google Scholar 

Hagihara M, Crandon JL, Urban CM, Nicolau DP (2013) KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy. Antimicrob Agents Chemother 57(2):1086–1088. https://doi.org/10.1128/AAC.01748-12Epub 2012 Dec 17. PMID: 23254422; PMCID: PMC3553679

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gill CM, Oliver A, Fraile-Ribot PA, Nicolau DP (2022) In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. J Antimicrob Chemother 77(10):2803–2808. https://doi.org/10.1093/jac/dkac232PMID: 35848936; PMCID: PMC9525071

Article  CAS  PubMed  PubMed Central  Google Scholar 

ECDC report (2023) Antimicrobial resistance surveillance in Europe.: 1-208

Lob SH et al (2020) In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples–SMART Surveillance Europe 2015–2017. J Med Microbiol 69(2):207–217

Article  CAS  PubMed  Google Scholar 

Gill CM et al (2021) Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa: implications for dose optimization. Antimicrob Agents Chemother 65(11):10–1128

Article  Google Scholar 

Gill CM, Nicolau DP, Global Study Group (2023) Piperacillin/Tazobactam Dose Optimization in the setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: time to Reconsider Susceptible Dose Dependent. Clin Ther 45(1):72–77

Article  CAS  PubMed  Google Scholar 

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2021) Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis.;72(7):e169-e183. https://doi.org/10.1093/cid/ciaa1478. PMID: 33106864

Mouton JW et al (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73(3):564–568

Article  CAS  PubMed  Google Scholar 

Roberts JA et al (2016) Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 194(6):681–691

Article  CAS  PubMed  Google Scholar 

Falagas ME et al (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56(2):272–282

Article  CAS  PubMed  Google Scholar 

Abdul-Aziz MH et al (2016) Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the defining antibiotic levels in intensive care unit patients (DALI) cohort. J Antimicrob Chemother 71(1):196–207

Article  CAS  PubMed  Google Scholar 

Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP (2024) Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye. Eur J Clin Microbiol Infect Dis 43(9):1787–1794. https://doi.org/10.1007/s10096-024-04896-7Epub 2024 Jul 12. PMID: 38995343

Article  CAS  PubMed  Google Scholar